{{Drugbox
| Verifiedfields = changed
| Watchedfields = changed
| verifiedrevid = 458270193
| image =  
<!-- Monoclonal antibody data -->
| type = mab
| mab_type = mab
| source = u
| target = TRAIL-R2
<!-- Clinical data -->
| tradename =  
| pregnancy_AU =  
| pregnancy_US =  
| pregnancy_category =  
| legal_AU =  
| legal_CA =  
| legal_UK =  
| legal_US =  
| legal_status =  
| routes_of_administration =  
<!-- Pharmacokinetic data -->
| bioavailability =  
| protein_bound =  
| metabolism =  
| elimination_half-life =  
| excretion =  
<!-- Identifiers -->
| CAS_number_Ref = {{cascite|changed|??}}
| CAS_number = 845816-02-6
| ATC_prefix = none
| ATC_suffix =  
| PubChem =  
| DrugBank_Ref = {{drugbankcite|correct|drugbank}}
| DrugBank =  
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = 967Q0SJD77
| KEGG_Ref = {{keggcite|correct|kegg}}
| KEGG = D06611
| ChemSpiderID_Ref = {{chemspidercite|changed|chemspider}}
| ChemSpiderID = none
<!-- Chemical data -->
| C=6346 | H=9832 | N=1720 | O=2002 | S=42
| molecular_weight = 143.6 kg/mol
}}

'''Lexatumumab''' (also known as '''ETR2-ST01''') is an experimental agonistic [[human]] [[monoclonal antibody]] against [[TRAIL-R2]] (DR5, APO-2) undergoing clinical trials for the treatment of [[cancer]].<ref>[http://www.ama-assn.org/ama1/pub/upload/mm/365/lexatumumab.pdf Statement on a Nonproprietary Name adopted by the USAN Council - Lexatumumab], ''American Medical Association''.</ref>

HGS-ETR2 antibodies were generated by HGS through a collaboration with [[Cambridge Antibody Technology]].<ref>http://www.hgsi.com/trail-receptor-antibodies-5.html</ref>

== References ==
<references/>

{{Monoclonals for tumors}}

[[Category:Monoclonal antibodies for tumors]]
[[Category:Experimental cancer drugs]]


{{monoclonal-antibody-stub}}
{{antineoplastic-drug-stub}}